These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3914816)

  • 61. The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP).
    Meier JJ; Gallwitz B; Siepmann N; Holst JJ; Deacon CF; Schmidt WE; Nauck MA
    Regul Pept; 2003 May; 113(1-3):95-100. PubMed ID: 12686467
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 63. GIP as a potential therapeutic agent?
    Meier JJ; Nauck MA
    Horm Metab Res; 2004; 36(11-12):859-66. PubMed ID: 15655720
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
    Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
    Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
    Nauck MA; Baller B; Meier JJ
    Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
    O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
    Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Dysfunction of the pancreatic beta cells observed in non-insulin-dependent diabetes].
    Waeber G
    Rev Med Suisse Romande; 1993 Sep; 113(9):695-8. PubMed ID: 8210896
    [No Abstract]   [Full Text] [Related]  

  • 70. Why is there still disagreement over insulin secretion in non-insulin-dependent diabetes?
    Ferner RE; Alberti KG
    Diabet Med; 1986 Jan; 3(1):13-7. PubMed ID: 2951128
    [No Abstract]   [Full Text] [Related]  

  • 71. Glucose-induced responses of insulin and gastric inhibitory polypeptide in various animal models.
    Ohneda A; Kobayashi T; Nihei J
    Tohoku J Exp Med; 1987 Jan; 151(1):97-104. PubMed ID: 3554613
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus.
    Meneilly GS; Elahi D
    J Am Geriatr Soc; 2006 Mar; 54(3):554-5. PubMed ID: 16551338
    [No Abstract]   [Full Text] [Related]  

  • 73. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
    Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Vølund A; Holst JJ; Krarup T
    Diabetes; 2007 Aug; 56(8):1951-9. PubMed ID: 17513701
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of dietary fibre on blood glucose, plasma immunoreactive insulin, C-peptide and GIP responses in non insulin dependent (type 2) diabetics and controls.
    Hagander B; Scherstén B; Asp NG; Sartor G; Agardh CD; Schrezenmeir J; Kasper H; Ahrén B; Lundquist I
    Acta Med Scand; 1984; 215(3):205-13. PubMed ID: 6328896
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gastric inhibitory polypeptide secretion after gastrectomy in patients with diabetes mellitus.
    Dousei T; Miyata M; Tanaka Y; Izukura M; Kawashima Y; Matsuda H
    Surg Today; 1993; 23(11):954-9. PubMed ID: 8292862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
    Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.
    Meier JJ; Hücking K; Holst JJ; Deacon CF; Schmiegel WH; Nauck MA
    Diabetes; 2001 Nov; 50(11):2497-504. PubMed ID: 11679427
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sustained oscillatory insulin secretion after pancreas transplantation.
    Kern W; Born J; Fehm HL; Kerner W
    Horm Metab Res; 1990 Dec; 22(12):644-6. PubMed ID: 2076862
    [No Abstract]   [Full Text] [Related]  

  • 79. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.
    Christensen MB; Lund A; Calanna S; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2018 Jan; 103(1):288-294. PubMed ID: 29099978
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The priming effect of glucose on the gastric inhibitory polypeptide-induced insulin release.
    Jorde R; Amland PF; Burhol PG
    Scand J Gastroenterol; 1986 Jan; 21(1):47-50. PubMed ID: 3513294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.